Evidera is looking to fill a position in Medical Writing and Communications. Location may be based on your experience and qualifications! Find out more about this job posting and many others in this week's HealthEconomics.Com Jobs Newsletter, your connection to the latest job openings in the Health […]
Gottlieb to Crack Down on Abuses by Big Drug Makers
FDA Commissioner Dr. Scott Gottlieb announced to a panel of U.S. policymakers plans to crack down on price gouging. The new commissioner outlined a plan he said would improve competition against branded drug makers. Among his top priorities, he said, is faster generic drug approvals to […]
Are These the Next Big Trends? 2017 ISPOR Award-Winner Says ‘Yes!’
In an interview with AJMC.com, Dr. James Chambers, winner of ISPOR's 2017 Bernie J. O'Brien New Investigator Award, discussed what he sees as the next big trends in the health care industry. Among them, Chambers says the industry will see expanded talks revolving around "value frameworks." He said […]
HealthCore: Pragmatic Trials Address Growing Demands of Payers, Policymakers
Real-world evidence (RWE) continues to play a crucial role in the health care industry, with a growing number of stakeholders relying on more robust data sets. It's doubly important now for product developers to adapt, and in their post-approval evidence portfolios spotlight the "combined safety, […]
Execs, Investors: Value-Based Pricing is Biggest Change Facing Industry
While value-based medicine is beginning to really take shape in the U.S., the approach has not been at the top of pharma professionals' agendas. However, that line of thinking is rapidly changing. According to a 2017 Global Healthcare Leaders survey conducted by Lazard, out of 200 pharmaceutical […]
The ACA Can’t Touch These 3 Trends
As the GOP's version of the Affordable Care Act awaits future Senate action, and much remains uncertain, there are three trends in the current health care system which will undoubedtly remain unchanged. For one, health care services will continue to expand as the U.S. population ages, and the […]
Study: RWE Infrequently Used in P&T Monographs and Therapeutic Class Reviews
According to a study funded by the National Pharmaceutical Council, real-world evidence (RWE) is infrequently used in pharmacy and therapeutic (P&T) class reviews and monographs. After analyzing 565 references cited in 27 monographs and therapeutic class reviews, researchers found therapeutic […]
WHO Commits to Biosimilar Medicine Prequalification Program
The World Health Organization (WHO) is planning on launching a new pilot program, a Biosimilar Medicine Prequalification Program, to assess cheap copies of expensive biotech cancer drugs, making these medicines more widely available. Find out more here. (Source: dispatch tribunal, 5/8/17) […]
New Framework Released for Demonstrating Value in Diagnostics
As American healthcare shifts from fee-for-service arrangement to a more value based system, the definition of value has been hard to nail down, with different stakeholders finding value in different areas. The Advanced Medical Technology Association (AdvaMed) recently released new frameworks to […]
How Would Physicians Choose to Replace the ACA?
Medscape recently kicked off a contest asking physicians, "How would you repeal or replace" the ACA? With over 600 submitting physicians, entries reflected different philosophies, themes and viewpoints, however, a notable percentage of physicians expressed support for single payer. Plans were judges […]
Gottlieb: Reducing Costs of Drugs Important Goal for FDA
The new Food and Drug Administration (FDA) Commissioner, Scott Gottlieb, says that even though the agency does not have a direct say in pricing, reducing pharmaceutical costs will be an important goal for the agency. Find out more here. (Source: Richard Staines, pharmaphorum, 5/18/17) […]
How Will Value-Based Deals Hold Up Without Patient Adherence?
Take a look at Amgen's Repatha and Sanofi and Regeneron's Praluent, two new cholesterol-lowering drugs launched with high expectations and a high price tag! After a value-based price contract, many questions have arisen as to the patients responsibility to correctly adhere to their prescription […]
England vs U.S. – A Look at the Redistribution and Redesign in Health Care
Policy makers in both England and the United States struggle with similar problems of redistribution and system design when it comes to health care. Both systems are in search of the "Holy Grail" of healthcare you might say, but have very different value systems and political goals fueling them. […]
What Do Your Google Searches Say About You?
Everybody Lies - Big Data, New Data, and What the Internet Can Tell Us About Who We Really Are, by Seth Stephens-Davidowitz, is now available for purchase! From the profound to the mundane, we can gain astonishing knowledge about the human psyche that less than twenty years ago, seemed unfathomable. […]
ICER Reviews Treatments for Tardive Dyskinesia
The Institute for Clinical and Economic Review (ICER) recently posted a Draft Scoping Document assessing the comparative clinical effectiveness and value of drugs for treatment of tardive dyskinesia. This report is expected to review three different drug treatments and will be open to public comment […]
Flexible Formularies – A New Patient-Centered Approach to Formulary Design
The current health reform debate will end in either a full replacement of the Affordable Care Act or, at the very least, a major facelift, but either way, patients are going to have to make some decisions about what constitutes value. Flexible formularies represent a new approach to designing […]
ICER Release Report on Abuse-Deterrent Opioids
The Institute for Clinical and Economic Review (ICER) recently released a Draft Evidence Report assessing the comparative clinical effectiveness and value of abuse-deterrent opioids. The report will be open for public comment until June 2, 2017. Find out more here. (Source: ICER, 5/5/17) […]
New Study Highlights Trumpcare’s Damage
The decade old health insurance expansion in Massachusetts has turned out to be a well-timed experiment offering real-world evidence as to a post Trumpcare healthcare system. This Massachusetts data is more concrete than an analysis from the Congressional Budget Office (CBO) would be and makes the […]
Is There a Breaking Point to Drug Pricing in the US?
How far can drug pricing keep increasing till it reaches the point in which it becomes unethical to treat a person? If there is a breaking point, who would decide it? Read more here. (Source: Alexandria Bachert, Medpage Today, 4/28/17) […]
Transparency is the Key to Trust in RWE and CER
This article explores four key barriers to the credibility of RWE and CER, and provides recommendations on specific actions that those conducting such studies can take in order to increase transparency and build trust in their data. Find out more here. (Source: Richard White, future science group, […]
GOP Removes AHCA Exemption of Congress
The House Rules Committee recently posted another proposed amendment to the American Health Care Act, removing the provision in the MacArthur amendment. The provision (Source: Timothy Jost, HealthAffairs Blog, 4/27/17) […]
Don’t Miss ISPOR’s HEOR Hands-on Training Course!
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) has planned a HEOR Short Course Program to take place during their 22nd Annual International Meeting to be held in Boston, MA, USA, May 20-24, 2017. Register for this hands-on training course here. (Source: ISPOR, 2017) […]
Gottlieb’s Views on ‘Gold Standard,’ Right-to-Try, LDTs, User Fees, FSMA & More
FDA Commissioner nominee, Scott Gottlieb, describes his views on regulations and gives a few hints on things that he would support if his nomination were to go through. Paid subscription required to read more. (Source: David Lim, InsideHealthPolicy.com) […]
MACRA Could Cause $250 Decrease in Hospital Reimbursement
A new study recently published in Health Affairs, found that hospitals would likely be most financially affected by changes from MACRA, potentially facing a $250 billion decrease over a 15-year period. Find out more here. (Source: Maria Castellucci, Modern Healthcare, 4/21/17) […]
How to Package Yourself for More HEOR Writing Business
Don't miss this FREE webinar, How to Package Yourself for More HEOR Writing Business, Wednesday, April 26, 12pm ET. You'll hear from a panel of two experienced HEOR Writers who will share insider knowledge of how they got started and what makes them so successful, and learn: *Ways to improve […]
Stephen Parente Nominated as HHS Deputy Secretary
Stephen Parente was recently nominated to be HHS' assistant secretary of planning and evaluation, a principal advisor to HHS Secretary Dr. Tom Price. Parente has been outspoken about the ACA, even predicting it's collapse back in 2014. Read more here. (Source: Dave Barkholz, 4/10/17) […]
How is Healthcare Uncertainty Affecting You?
Susan Cantrell, CEO of the Academy of Managed Care Pharmacy speaks out about the uncertainty of the American healthcare system and how it is affecting everyone in healthcare. Watch this short video clip as she talks about how to deal with that uncertainty and how to keep focused on what matters - […]
5 Reasons Why Your Advisory Board Needs a Medical Writer
Maybe you've heard you could benefit from having a medical writer, but you're not sure why? Ginny Vachon, Founder and Principal Medical Writer at Principal Medvantage explains how having an independent medical writer for your upcoming advisory board can help your team get the most from your meeting. […]
PIE Legislation Officially Introduced in Congress
The Pharmaceutical Information Exchange (PIE) Act of 2017 has recently been introduced by Rep. Brett Guthrie (R-KY). This bill aims to improve patient access to emerging medication therapies by clarifying the scope of permitted health care economic and scientific information communications between […]
Cancer Experts Condemn Recent NICE Decision
The National Institute for Health and Care Excellence recently issued a new draft guidance refusing to recommend nivolumab for the treatment of head and neck cancer. Expert cancer clinicians however, have condemned the decision. Find out more here. (Source: Adrian O'Dowd, onmedica, 4/11/17) […]
